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The occurrence of granulocytic sarcoma as a pattern of relapse after allogeneic hema-
topoietic stem cell transplantation (allo-HSCT) is rare. In this paper, we report a rare case 
of acute myeloid leukemia (AML) relapsed as a granulocytic sarcoma of the donor type. 
The patient was diagnosed as having AML and underwent an allo-HSCT from his matched 
sibling donor. Fifty-seven months after allo-HSCT, he developed granulocytic sarcomas 
of duodenum, jejunum, and left sterno-cleido-mastoid muscle. The bone marrow was 
normal with 100% donor chimerism. A Y chromosome PCR was performed on the pa-
tient’s duodenum specimen as well as bone marrow aspirate in order to check the pa-
tient-origin cells. The duodenal specimen was found to contain 41.2% SRY-positive cells 
(from the donor). Repeat endoscopy on day 2 of chemotherapy showed that the gran-
ulocytic sarcoma had shrunk dramatically. The patient died of sepsis during the nadir state 
35 days after starting salvage chemotherapy.
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INTRODUCTION
  Isolated extramedullary relapses of granulocytic sarcoma 
(GS) of acute myeloid leukemia (AML) after allogeneic hema-
topoietic stem cell transplantation (allo-HSCT) are reported 
to be rare and are usually followed by bone marrow relapses 
[1]. GS was first described by Burns in 1811 and subsequently 
termed “chloroma” by King in 1853. The association of chlor-
oma with leukemia was first reported in 1904. The term 
“granulocytic sarcoma” was first used by Rappaport in 1967. 
Little is known concerning the mechanism of GS develop-
ment, but the prognosis of patients with GS of AML is less 
favorable than that of AML patients with bone marrow re-
lapse only [1-3]. Here, we present the case of a patient 
with AML who developed GS of donor origin defined to 
his duodenal mucosa, jejunum, and left sterno-cleido-mastoid 
(SCM) muscle 57 months after allo-HSCT and without any 
evidence of bone marrow recurrence. 
CASE REPORT
  A 35-year-old man presented with fever, weight loss, and 
a sore throat, which had persisted for 2 months. He was 
diagnosed as having AML with positive expression of CD3, 
CD5, CD7, CD13, CD22, CD33, CD34, and cytoplasmic 
myeloperoxidase. Cytogenetic analysis of the leukemic cells 
showed a normal 46, XY karyotype. He was initially treated 
with idarubicin (12 mg/m
2/d for 3 days) and cytarabine (200 
mg/m
2/d for 7 days). Follow-up bone marrow biopsy per-
formed 28 d after the completion of chemotherapy showed 
complete remission of the acute leukemia. After 1 cycle 
of consolidation chemotherapy using the same regimen as 
used previously, the patient underwent an allo-HSCT from 
his HLA full-matched sibling (sister) donor. The conditioning 
regimen for the allo-HSCT was a combination of busulfan 
(4 mg/kg for 4 days) and cyclophosphamide (60 mg/kg for 
2 days). Cyclosporine and methotrexate were administered 
for graft versus host disease (GVHD) prophylaxis after the 
allo-HSCT. Morphological complete remission and complete 
donor chimerism were confirmed by a bone marrow biopsy Korean J Hematol 2010;45:70-2.
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Fig. 1. Endoscopic findings of the duodenal mucosal lesion.
Fig. 2. Infiltrating cells were immunoreactive for CD34. Immunohisto-
chemical stain. ×400.
Fig. 3. Multiplex short tandem repeat polymerase chain
reaction performed for the duodenal biopsy specimen 
shows that 41.2% of the cells were of donor origin.
and chimerism study, respectively, performed at D+28 after 
the HSCT. Ten months after the HSCT, grade III GVHD 
developed in the patient’s liver; however, this was success-
fully treated with steroids and cyclosporin. Fifty-seven 
months after the HSCT, the patient developed gastro-
intestinal (GI) symptoms of nausea, vomiting, and epigastric 
pain. Endoscopic examination revealed a mass lesion growing 
into the lumen of the second portion of the duodenum (Fig. 
1), and subsequent biopsy confirmed the duodenal lesion 
as a GS (Fig. 2). Multiple jejunal mass involvement was 
observed on a computed tomography (CT) scan. The bone 
marrow was, nevertheless, free of acute leukemic blast cells 
and a chimerism study again showed complete donor 
chimerism. The chimerism study performed on a duodenal 
biopsy specimen by multiplex short tandem repeat amplifica-
tion revealed that 41.2% of the cells were of donor origin 
(Fig. 3). During the period of evaluation of the duodenal 
lesion and bone marrow, the patient developed a mass lesion 
in his left SCM muscle. The specimen obtained from the 
n e c k  m a s s  b y  n e e d l e  a s p i r a t i on biopsy also showed ag-
gregations of acute leukemic cells. The patient was ad-
ministered second-line induction chemotherapy comprising 
mitoxantrone (10 mg/m
2/d for 3 days), etoposide (100 
mg/m
2/d for 4 days), and cytarabine (2,000 mg/m
2/d for 5 
days). Repeated endoscopy on day 2 of the chemotherapy 
showed that the GS had shrunk dramatically. However, 
pneumonia and sepsis developed during a neutropenic period 
after chemotherapy and the patient died of septic shock.
DISCUSSION
  The incidence of GS in the course of AML has been re-
ported to range from 3% to 4.7% [4]. Cases of isolated extra-
medullary relapse of myeloid malignancies following an al-
lo-HSCT are much rarer [5]. There appears to be a tendency 
for acute leukemias to relapse in soft tissue and to continue 
to relapse in soft tissues more often than in bone. Frequent 
sites of involvement are the skin, head and neck area, breast, Korean J Hematol 2010;45:70-2.
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bone, testis, and serosa; however, sites such as the GI tract, 
pancreas, heart, and appendix are also reported to be in-
volved, although rarely [6-10]. GI tract involvement is con-
siderably rarer than that of the other sites with only few 
cases reported [4, 7, 11].
  In a retrospective survey conducted by European trans-
plantation centers, only 0.65% of patients with AML under-
going allo-HSCT developed isolated extramedullary recur-
rences, and 95% of these were followed by a bone marrow 
relapse within 1-12 months of diagnosis [1]. Since our patient 
developed involvement at another site during the evaluation 
period of the duodenal GS, subsequent development of bone 
marrow involvement was considered highly probable. The 
risk period for first extramedullary relapse in acute lympho-
blastic lymphoma appears to be 2 years after transplantation; 
however, in myeloid leukemias, one-third of the cases oc-
curred after 2 years [7]. In our case, GS developed 57 months 
after transplantation. 
  Donor cell-origin leukemic recurrence after allo-HSCT 
has been reported in several cases; however, donor cell-origin 
GS is extremely rare [12-14]. A report from Italy described 
a patient who suffered 2 recurrences of GS of patient cell 
origin and a third recurrence with leukemia mixed with 
cells of donor origin [13]. In the patient from Italy, sub-
sequent bone marrow recurrence with patient-origin leuke-
mia also developed. In our patient, a chimerism study re-
vealed that 41.2% of cells were of donor origin. It is reason-
able to consider that the GS developed from donor cells 
and mixed with the intestinal epithelium of the patient dur-
ing endoscopic biopsy. To the best of our knowledge, this 
is the second report of GS of donor cell origin and the 
first report of GS of donor origin involving the GI tract.
  Extramedullary relapse following allo-HSCT is a very poor 
prognostic sign [4, 5, 15]. Unless the initial treatment is 
adequate, a single relapse focus is almost invariably followed 
by other extramedullary relapses, usually within months 
[7]. Once a single focus is clinically observed, it is likely 
that other sites will become evident if aggressive systemic 
treatment is not undertaken expeditiously, even when the 
marrow shows no leukemic cells [7]. When more than 1 
site is evident, durable remission and disease-free survival 
have rarely been reported. Extramedullary relapse has typi-
cally not been successfully treated with local therapy alone, 
even when the bone marrow shows donor cells and no leuke-
mia [7]. In such instances, local radiotherapy (RT) could 
be a treatment option. From the European data, 3 out of 
6 patients treated with local RT without chemotherapy 
showed long-term survival; however, local RT to the GI 
tract is limited by its toxicity [1]. In our case, the disease 
progression was extremely fast, and within a couple of days 
further extramedullary site involvement in his left SCM mus-
cle was observed. Although the GS shrunk markedly after 
combination chemotherapy, the patient failed to recover 
from sepsis. Management of extramedullary recurrences in 
the post-transplantation setting is extremely difficult because 
of the cumulative toxicities of previous high-dose chemothe-
rapy. Investigation of an optimal treatment strategy is there-
f o r e  n e e d e d  i n  o r d e r  t o  m a n a g e  h i g h l y  a g g r e s s i v e  G S  i n  
fragile patients after HSCT.
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